NANO 24 LTD
General Data
Reg Number
516204989
Sector
Biomed
Established
2019
No. of Employees
10
Stage
R&D
Additional Funding
0
Technology
Nano24 is developing a pipeline of CD24-based exosomes, aimed at treating COVID-19 with EXO-CD24, a therapeutic directly inhaled to the lungs, as well as a broad range of disease areas, spanning ARDS, respiratory and autoimmune disease.
Targeted Customers
Physicians, People with ARDS, Respiratory and Autoimmune disease.
Winning details
Route name
Winning year
Increasing participation of Israeli industrial corporations in the European Horizon program
Increasing participation of Israeli industrial corporations in the European Horizon program
2025